ES2088770A1 - Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. - Google Patents

Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.

Info

Publication number
ES2088770A1
ES2088770A1 ES09500363A ES9500363A ES2088770A1 ES 2088770 A1 ES2088770 A1 ES 2088770A1 ES 09500363 A ES09500363 A ES 09500363A ES 9500363 A ES9500363 A ES 9500363A ES 2088770 A1 ES2088770 A1 ES 2088770A1
Authority
ES
Spain
Prior art keywords
polypodium
neuroimmune
dysfunctions
cognitive
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09500363A
Other languages
English (en)
Other versions
ES2088770B1 (es
Inventor
Almagro Eliseo Quintanilla
Alperi Joaquin Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Especialidades Farmaceuticas Centrum SA
Original Assignee
Especialidades Farmaceuticas Centrum SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES9500363A priority Critical patent/ES2088770B1/es
Application filed by Especialidades Farmaceuticas Centrum SA filed Critical Especialidades Farmaceuticas Centrum SA
Priority to AT95500063T priority patent/ATE222112T1/de
Priority to DE69527742T priority patent/DE69527742T2/de
Priority to EP95500063A priority patent/EP0680762B1/en
Priority to PT95500063T priority patent/PT680762E/pt
Priority to DK95500063T priority patent/DK0680762T3/da
Priority to US08/433,621 priority patent/US5601829A/en
Priority to JP7134773A priority patent/JP2779780B2/ja
Publication of ES2088770A1 publication Critical patent/ES2088770A1/es
Application granted granted Critical
Publication of ES2088770B1 publication Critical patent/ES2088770B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA CON ACTIVIDAD EN EL TRATAMIENTO DE DISFUNCIONES COGNITIVAS Y/O NEUROINMUNES, EN ESPECIAL DE LA ENFERMEDAD DE ALZHEIMER. LA COMPOSICION COMPRENDE UN EXTRACTO HIDROSOLUBLE NATURAL AISLADO DEL RIZOMA Y HOJAS DE PHLEBODIUM DECUMANUM, POLYPODIUM AUREUM, POLYPODIUM LEUCOTOMOS, POLYPODIUM VULGARE, POLYPODIUM TRISERIALE, PTERIDIUM AQUILINUM, DRYOPTERIS CRASSIRHIZOMA Y CYATHEA TAIWANIANA, Y UN VEHICULO FAMACEUTICAMENTE ACEPTABLE. LA COMPOSICION COMPRENDE ADEMAS LA FRACCION SOLUBLE EN ALCOHOL Y LA FRACCION LIPOSOLUBLE DERIVADAS DE DICHO EXTRACTO.
ES9500363A 1994-05-06 1995-02-23 Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. Expired - Fee Related ES2088770B1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES9500363A ES2088770B1 (es) 1995-02-23 1995-02-23 Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
DE69527742T DE69527742T2 (de) 1994-05-06 1995-04-27 Pharmazeutische Zusammensetzung enthaltend Farnextrakt(e) zur Behandlung von neurodegenerativen Krankheiten.
EP95500063A EP0680762B1 (en) 1994-05-06 1995-04-27 Pharmaceutical composition comprising fern extract(s) for the treatment of neurodegenerative diseases.
PT95500063T PT680762E (pt) 1994-05-06 1995-04-27 Composicao farmaceutica compreendendo extracto(s) de feito para tratamento de disfuncoes neurodegenerativas
AT95500063T ATE222112T1 (de) 1994-05-06 1995-04-27 Pharmazeutische zusammensetzung enthaltend farnextrakt(e) zur behandlung von neurodegenerativen krankheiten.
DK95500063T DK0680762T3 (da) 1994-05-06 1995-04-27 Farmaceutisk sammensætning til brug i behandlingen af neurodegenerative dysfunktioner
US08/433,621 US5601829A (en) 1994-05-06 1995-05-03 Pharmaceutical composition of activity in the treatment of cognitive and/or neuroimmune dysfunctions
JP7134773A JP2779780B2 (ja) 1994-05-06 1995-05-08 認識機能不全治療剤及び／又はアルツハイマー病治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9500363A ES2088770B1 (es) 1995-02-23 1995-02-23 Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.

Publications (2)

Publication Number Publication Date
ES2088770A1 true ES2088770A1 (es) 1996-09-01
ES2088770B1 ES2088770B1 (es) 1997-03-16

Family

ID=8289566

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9500363A Expired - Fee Related ES2088770B1 (es) 1994-05-06 1995-02-23 Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.

Country Status (1)

Country Link
ES (1) ES2088770B1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124675A1 (es) * 1997-07-30 1999-02-01 Helsint S A L Helechos Interna "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida".
WO1999006058A1 (es) * 1997-07-30 1999-02-11 Helsint, S.A.L. Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer
ES2137900A1 (es) * 1998-06-02 1999-12-16 Helsint S A L Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos.
WO2000043022A1 (es) * 1999-01-22 2000-07-27 Helsint, S.A.L. Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobreesfuerzo fisico

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES470204A1 (es) * 1978-05-24 1979-01-01 Conrad Ltd Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica
ES8104315A1 (es) * 1980-04-02 1981-04-16 Conrad Ltd Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae.
EP0503208A1 (en) * 1991-03-08 1992-09-16 Maracuyama International, S.A. Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2068163A1 (es) * 1994-05-06 1995-04-01 Esp Farmaceuticas Centrum Sa Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES470204A1 (es) * 1978-05-24 1979-01-01 Conrad Ltd Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica
ES8104315A1 (es) * 1980-04-02 1981-04-16 Conrad Ltd Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae.
EP0503208A1 (en) * 1991-03-08 1992-09-16 Maracuyama International, S.A. Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2068163A1 (es) * 1994-05-06 1995-04-01 Esp Farmaceuticas Centrum Sa Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124675A1 (es) * 1997-07-30 1999-02-01 Helsint S A L Helechos Interna "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida".
WO1999006058A1 (es) * 1997-07-30 1999-02-11 Helsint, S.A.L. Fracciones hidrosolubles de phlebodium decumanum y su empleo como complemento nutricional en pacientes de sida y cancer
ES2137900A1 (es) * 1998-06-02 1999-12-16 Helsint S A L Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos.
WO2000043022A1 (es) * 1999-01-22 2000-07-27 Helsint, S.A.L. Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobreesfuerzo fisico
ES2146555A1 (es) * 1999-01-22 2000-08-01 Helsint S A L Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico.

Also Published As

Publication number Publication date
ES2088770B1 (es) 1997-03-16

Similar Documents

Publication Publication Date Title
PT680762E (pt) Composicao farmaceutica compreendendo extracto(s) de feito para tratamento de disfuncoes neurodegenerativas
AU5943096A (en) Dermatological or pharmaceutical composition, preparation process and use
WO1999032097A3 (en) Phytosterol composition for preventing alzheimer's disease
NZ305822A (en) Isolated presenilin genes and use in diagnosing Alzheimer's Disease
RS49963B (sr) Kompozicija koja obuhvata hranjivi materijal i biljni ekstrat korisna za prevenciju i tretiranje virusa humane imunodeficijencije i drugih infektivnih bolesti
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2210751A1 (en) Anti-cd6 monoclonal antibodies and their uses
AU5229793A (en) Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics
HUP0003041A3 (en) Stable extract of hypericum perforatum l., a method for producing the same, and corresponding pharmaceutical preparations
WO1999007401A3 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
CA2325360A1 (en) Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases
AU2001265885A1 (en) Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
ES2088770A1 (es) Una composicion farmaceutica con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
CA2354039A1 (en) Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
AU5103196A (en) Form of administration for applying pharmaceutical substances and auxiliary substances, and process for the preparation thereof
ES2068163B1 (es) Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
AUPM855194A0 (en) Controlled-release pharmaceutical preparations
Wolfhagen et al. Can ursodeoxycholic acid induce disease remission in primary biliary cirrhosis? The Dutch Multicentre PBC Study Group
AU3478600A (en) Treatment of autoimmune diseases with american ginseng extract
WO2002002755A3 (en) Regulation of human thimet oligopeptidase-like enzyme
AU1939697A (en) Physiologically active substances tkr1785's, process for the preparation thereof, and microbe
USD375363S (en) Combined upper leg and thigh spacer device for the physically impaired
AU1815695A (en) Animal model of the alzheimer disease, preparation and utilisations

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19960901

Kind code of ref document: A1

Effective date: 19960901

FD2A Announcement of lapse in spain

Effective date: 20180806